The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear¥165.13Fair value¥1,483.85Bull¥2,041.97
FairClose
52-week traded range
52W low ¥986.0052W high ¥1,235.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
CREATE MEDIC CO.,LTD. closed at ¥1,133.00, 23.6% below the consensus fair value of ¥1,483.85 drawn from 9 valuation models.
Financial DNA score 65/100 — Strong. P/E of 13.5x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
¥180.93
-84.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=2%, r=10%, tg=3%, n=10yr
Graham Number
¥1,924.32
+69.8%
√(22.5 × EPS × BVPS)
EPS=84.25, BVPS=1953.45
P/E Fair Value
¥1,685.00
+48.7%
EPS × 20x (sector P/E)
EPS=84.25, Sector P/E=20x
Peter Lynch (PEG)
¥165.13
-85.4%
EPS × Growth% (PEG = 1 is fair)
EPS=84.25, g=2%
EV/EBITDA
¥2,041.97
+80.2%
(EBITDA × 11x − Net Debt) ÷ Shares
EBITDA=1.58B
Dividend Discount (DDM)
¥573.50
-49.4%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=44.98, r=10%, g=2%
Book Value (P/B)
¥390.69
-65.5%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=1953.45, ROE=4.4%, g=3%, r=10%
Reverse DCF
¥1,133.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 1.8% | Historical: 2%
Margin of Safety
¥947.56
-16.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=1263.42, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.